Clinical Trials Logo

Filter by:
  • Available  
  • Page [1]
NCT ID: NCT05795361 Available - Hunter Syndrome Clinical Trials

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Start date: n/a
Phase:
Study type: Expanded Access

As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies will be closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.

NCT ID: NCT04578444 Available - Clinical trials for HER2-Positive Advanced Biliary Tract Cancer

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.

NCT ID: NCT03994627 Available - Soft Tissue Sarcoma Clinical Trials

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

NCT ID: NCT03763604 Available - Clinical trials for Metastatic Breast Cancer

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.